Camptothecins New Anticancer Agents

Introduction, M. Potmesil and H.M. Pinedo Biochemistry of Camptothecin, L.F. Liu Camptothecin and Analogues: From Discovery to Clinic, M.E. Wall and M. Wani Twenty Years Later: Review of Clinical Trials with Camptothecin Sodium (NSC-100880), F. Muggia Preclinical Development of 20(S)-Camptothecin, 9-Aminocamptothecin and Other Analogues, M. Potmesil and B.C. Giovanella Phase I Clinical Trial and Pharmacokinetic Results with Oral Administration of 20(S)-Camptothecin, J.S. Stehlin, E.A. Natelson, H.R. Hinz, B.C. Giovanella, P.D. de Ipolyi, K.M. Fehir, T.P. Trezona, D.M. Vardeman, N.J. Harris, A.K. Marcee, A.J. Kozielski, and A. Ruiz-Razura Clinical Studies of CPT-11 in Japan, T. Taguchi Clinical Trials and Pharmacokinetic Studies of CPT-11 in the United States, M.L. Rothenberg, E.K. Rowinksy, J.G. Kuhn, H.A. Burris, III, R.C. Donehower, and D.D. Von Hoff CPT-11: Clinical Trials and Pharmacology Studies of CPT-11 and its Active Metabolite SN-38 in France: Preliminary Pharma cokinetic-Pharmacodynamic Relationships, G.G. Chabot, M. de Forni, D. Abigerges, J.-.P Armand, M. Clavel, R. Bugat, S. Culine, J.-M. Extra, M. Marty, M.-C. Bissery, A. Mathieu-BouT, P. HTrait, and A. Gouyette Topotecan Clinical Trials in the United States, H. Hochster Clinical Trials of Topotecan in Europe, J. Verweij, W.T.B. Huinink, B. Lund, A. Planting, J. Beijnen, M. de Boer-Dennert, H. Rosing, I. Koier, and H. Hansen Camptothecins: Dose-Limiting Toxicities and their Management, H.A. Burris, III, S.M. Fields, J.G. Kuhn, and D.D. Von Hoff Cellular Determinants of Sensitivity and Resistance to Camptothecins, Y. Pommier, A. Tanizawa, K. Okada, and T. Andoh The Perspectives, M. Potmesil and H.M. Pinedo